A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Adenocarcinoma at High Risk for Recurrence Using Epigenetic Therapy
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Azacitidine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 Oct 2017 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.
- 09 Oct 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2018.